Eros Therapy™ Information

FDA-Cleared Treatment

• Eros Therapy has been cleared by the FDA as a prescription device to treat symptoms of Female Sexual Dysfunction (FSD) caused by inadequate blood flow to the genitalia.
• By causing clitoral engorgement, Eros Therapy has been clinically demonstrated to significantly improve sensation, lubrication, ability to achieve orgasm and overall sexual satisfaction in women with FSD.

How Does Eros Therapy Work?

• Designed for at-home patient use with a prescription from a licensed physician.
• Eros Therapy creates a gentle vacuum over the clitoris to increase blood flow to the genitalia.
• This increase in arterial blood flow causes the clitoris to become engorged and a chain reaction begins:

1. The arteries expand to accommodate the additional blood. As a result, pressure is applied to the nerves, which causes clitoral sensation and sexual stimulation.
2. The reflexive increase in blood flow to the vagina increases vaginal lubrication, facilitates intercourse and increases ability to achieve orgasm.

Clinical Trials in the United States

• Principle investigators — Kevin Billups, M.D., Metropolitan Urology Specialists (St. Paul/ Minneapolis); Irwin Goldstein, M.D., Professor of Urology, Boston University Medical Center (Boston)
• Results — High success for increased sensation, vaginal lubrication, orgasm and overall sexual satisfaction.
• Leading U.S. gynecologists and urologists are conducting additional trials including clinical studies in women with cervical cancer and diabetic women.

Eros Therapy Around the World

• UroMetrics maintains the Conformite Europeenne (CE) Mark approval for Eros Therapy, allowing its marketing in all European Union countries, subject to limited regulations in certain countries.
• Currently available in Australia, Canada, Europe, Latin American and the United States.

Clinical Trial Results

Results after using device	Sensation		Orgasm		Sexual Satisfaction		Lubrication
	Women w/ FSD (%)	Women w/o FSD (%)	Women w/ FSD (%)	Women w/o FSD (%)	Women w/ FSD (%)	Women w/o FSD (%)	Women w/ FSD (%)	Women w/o FSD (%)
More than before	90	58	55	42	80	25	80	33
Same as before	10	42	45	58	20	75	20	58
Less than before	0	0	0	0	0	0	0	0
Couldn’t tell, partner yes	0	0	0	0	0	0	0	9